ArticleHealth science reports2026
Lessons From Astaxanthin Therapy to Combat Oral Premalignant and Malignant Lesions: A Narrative Review.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Oral cancer is one of the most common head and neck malignancies and remains associated with high morbidity, mortality, and treatment-related toxicity. Despite advances in surgery, radiotherapy, and chemotherapy, there is still a need for safer adjunctive therapies with better therapeutic potential. Results: Astaxanthin, a natural lipophilic carotenoid, has gained attention because of its antioxidant, anti-inflammatory, and anticancer activities. The available evidence suggests that astaxanthin may suppress oral premalignant and malignant progression by inhibiting inflammation, oxidative stress, proliferation, invasion, angiogenesis, and survival signaling pathways, while promoting apoptosis and reactivating tumor suppressor mechanisms. Preclinical studies also indicate that astaxanthin-based formulations may improve delivery efficiency and enhance antitumor effects in oral cancer models. Conclusion: Overall, astaxanthin appears to be a promising natural candidate for oral cancer prevention and treatment. However, most findings are based on preclinical studies, and further well-designed clinical investigations are required to confirm its efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.